BR112022012867A2 - Tratamento de câncer com inibidores de cdk12/13 - Google Patents

Tratamento de câncer com inibidores de cdk12/13

Info

Publication number
BR112022012867A2
BR112022012867A2 BR112022012867A BR112022012867A BR112022012867A2 BR 112022012867 A2 BR112022012867 A2 BR 112022012867A2 BR 112022012867 A BR112022012867 A BR 112022012867A BR 112022012867 A BR112022012867 A BR 112022012867A BR 112022012867 A2 BR112022012867 A2 BR 112022012867A2
Authority
BR
Brazil
Prior art keywords
cdk12
inhibitors
cancer treatment
cancer
treatment
Prior art date
Application number
BR112022012867A
Other languages
English (en)
Inventor
A Murphy Eric
Tyhonas John
Timple Noelito
Kanouni Toufike
D Arnold Lee
Gardiner Elisabeth
Martin Eric
Original Assignee
Kinnate Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinnate Biopharma Inc filed Critical Kinnate Biopharma Inc
Publication of BR112022012867A2 publication Critical patent/BR112022012867A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

TRATAMENTO DE CÂNCER COM INIBIDORES DE CDK12/13. São fornecidas nesse relatório descritivo composições e métodos para o tratamento de um câncer de mama triplo-negativo, câncer ovariano e câncer de próstata resistente à castração. As referidas composições compreendem inibidores de CDK12/13.
BR112022012867A 2019-12-31 2020-12-23 Tratamento de câncer com inibidores de cdk12/13 BR112022012867A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962956114P 2019-12-31 2019-12-31
PCT/US2020/066967 WO2021138215A1 (en) 2019-12-31 2020-12-23 Treatment of cancer with cdk12/13 inhibitors

Publications (1)

Publication Number Publication Date
BR112022012867A2 true BR112022012867A2 (pt) 2022-09-06

Family

ID=76686778

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022012867A BR112022012867A2 (pt) 2019-12-31 2020-12-23 Tratamento de câncer com inibidores de cdk12/13

Country Status (11)

Country Link
US (1) US20230074545A1 (pt)
EP (1) EP4085053A4 (pt)
JP (1) JP2023508996A (pt)
KR (1) KR20220123064A (pt)
CN (1) CN115175899A (pt)
AU (1) AU2020417223A1 (pt)
BR (1) BR112022012867A2 (pt)
CA (1) CA3166386A1 (pt)
IL (1) IL294392A (pt)
MX (1) MX2022008099A (pt)
WO (1) WO2021138215A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3787629A4 (en) 2018-05-02 2022-01-05 Kinnate Biopharma Inc. INHIBITORS OF CYCLINE-DEPENDENT KINASES
BR112020026748A2 (pt) 2018-06-29 2021-03-30 Kinnate Biopharma Inc. Inibidores de quinases dependentes de ciclina
WO2023102184A1 (en) * 2021-12-03 2023-06-08 Incyte Corporation Bicyclic amine compounds as cdk12 inhibitors
WO2024032561A1 (en) * 2022-08-08 2024-02-15 Insilico Medicine Ip Limited Inhibitors of cyclin-dependent kinase (cdk) 12 and/or cdk13 and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101917982B (zh) * 2007-11-12 2013-03-20 彼帕科学公司 使用4-碘-3-硝基苯甲酰胺与抗肿瘤剂组合治疗乳腺癌
AU2014337067B2 (en) * 2013-10-18 2019-01-24 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
EP3787629A4 (en) * 2018-05-02 2022-01-05 Kinnate Biopharma Inc. INHIBITORS OF CYCLINE-DEPENDENT KINASES
BR112020026748A2 (pt) * 2018-06-29 2021-03-30 Kinnate Biopharma Inc. Inibidores de quinases dependentes de ciclina

Also Published As

Publication number Publication date
EP4085053A1 (en) 2022-11-09
EP4085053A4 (en) 2023-12-27
CA3166386A1 (en) 2021-07-08
WO2021138215A1 (en) 2021-07-08
CN115175899A (zh) 2022-10-11
IL294392A (en) 2022-08-01
AU2020417223A1 (en) 2022-07-14
MX2022008099A (es) 2022-07-11
KR20220123064A (ko) 2022-09-05
US20230074545A1 (en) 2023-03-09
JP2023508996A (ja) 2023-03-06

Similar Documents

Publication Publication Date Title
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
BR112022012867A2 (pt) Tratamento de câncer com inibidores de cdk12/13
CO2020009861A2 (es) Inhibidores pd-1/pd-l1
CO2021000151A2 (es) Inhibidores de pd-1/pd-l1
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
CL2018003316A1 (es) Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786)
WO2018140831A3 (en) Tumor targeting conjugates and methods of use thereof
PH12019501663A1 (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
GB2557123A (en) Modified cells and methods of therapy
ZA201906832B (en) Novel psma-binding agents and uses thereof
MX2022005780A (es) Moduladores de receptores estrogenicos.
BR112018008326A2 (pt) composições e métodos para o tratamento de câncer
NZ742787A (en) Compositions comprising bacterial strains
MX2019008158A (es) Terapia de combinacion para el tratamiento del cancer.
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
CL2008003200A1 (es) Compuestos derivados de tiazol, inhibidores de la proteina quinasas; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de vejiga, de mama y de rinon.
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
BR112022008365A2 (pt) Inibidores de cd73
MY200161A (en) Bacteria for targeting tumors and treating cancer
MX2018001369A (es) Combinaciones de inhibidores de tirosina quinasa de bruton y sus usos.
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
BR112018009745A8 (pt) compostos heterocíclicos para o tratamento de doença
WO2016130581A8 (en) Combination cancer therapy
BR112022001336A2 (pt) Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]